W
Wolfgang P. Fendler
Researcher at University of California, Los Angeles
Publications - 180
Citations - 7246
Wolfgang P. Fendler is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 34, co-authored 129 publications receiving 4867 citations. Previous affiliations of Wolfgang P. Fendler include St. Vincent's Health System & University of Duisburg-Essen.
Papers
More filters
Journal ArticleDOI
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Kambiz Rahbar,Hojjat Ahmadzadehfar,Clemens Kratochwil,Uwe Haberkorn,Michael Schäfers,Markus Essler,Richard P. Baum,Harshad R. Kulkarni,Matthias Schmidt,Alexander Drzezga,Peter Bartenstein,Andreas Pfestroff,Markus Luster,Ulf Lützen,Marlies Marx,Vikas Prasad,Winfried Brenner,Alexander Heinzel,Felix M. Mottaghy,Juri Ruf,Philipp T. Meyer,Martin Heuschkel,Maria Eveslage,Martin Bögemann,Wolfgang P. Fendler,Bernd J. Krause +25 more
TL;DR: The present retrospective multicenter study of 177Lu-PSMA-617 RLT demonstrates favorable safety and high efficacy exceeding those of other third-line systemic therapies in mCRPC patients.
Journal ArticleDOI
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P. Fendler,Wolfgang P. Fendler,Matthias Eiber,Matthias Eiber,Mohsen Beheshti,Jamshed Bomanji,Francesco Ceci,Steven Cho,Frederik L. Giesel,Uwe Haberkorn,Thomas A. Hope,Klaus Kopka,Bernd J. Krause,Felix M. Mottaghy,Heiko Schöder,John Sunderland,Simon Wan,Hans-Juergen Wester,Stefano Fanti,Ken Herrmann +19 more
TL;DR: These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
Journal ArticleDOI
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler,Wolfgang P. Fendler,Jeremie Calais,Matthias Eiber,Matthias Eiber,Robert R. Flavell,Ashley Mishoe,Felix Y. Feng,Hao G. Nguyen,Robert E. Reiter,Matthew Rettig,Shozo Okamoto,Louise Emmett,Helle D Zacho,Harun Ilhan,Axel Wetter,Christoph Rischpler,Heiko Schöder,Irene A. Burger,Jeannine Gartmann,Raven Smith,Eric J. Small,Roger Slavik,Peter R. Carroll,Ken Herrmann,Ken Herrmann,Johannes Czernin,Thomas A. Hope +27 more
TL;DR: Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.
Journal ArticleDOI
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber,Matthias Eiber,Ken Herrmann,Jeremie Calais,Boris Hadaschik,Frederik L. Giesel,Markus Hartenbach,Thomas A. Hope,Robert E. Reiter,Tobias Maurer,Wolfgang A. Weber,Wolfgang P. Fendler,Wolfgang P. Fendler +12 more
TL;DR: A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
Journal ArticleDOI
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Jeremie Calais,Francesco Ceci,Francesco Ceci,Matthias Eiber,Matthias Eiber,Thomas A. Hope,Michael S Hofman,Christoph Rischpler,Tore Bach-Gansmo,Cristina Nanni,Bital Savir-Baruch,David Elashoff,Tristan Grogan,Magnus Dahlbom,Roger Slavik,Jeannine Gartmann,Kathleen Nguyen,Vincent Lok,Hossein Jadvar,Amar U. Kishan,Matthew Rettig,Robert E. Reiter,Wolfgang P. Fendler,Wolfgang P. Fendler,Johannes Czernin +24 more
TL;DR: Comparing prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations found PSMA should be the PET tracer of choice when PET- CT imaging is considered for subsequent treatment management decisions.